Clinical results with direct thrombin inhibitors

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 3, 2002, Pages 36-38

  Nicolaides, Andrew N ^a,b  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Direct thrombin inhibitors; Hirudin

Indexed keywords

ARGATROBAN; DALTEPARIN; EFEGATRAN; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; MELAGATRAN; STREPTOKINASE;

ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KNEE ARTHROPLASTY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS;

ANTICOAGULANTS; CORONARY DISEASE; HUMANS; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0345377866     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069107     Document Type: Review

References (26)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors. J Clin Invest 1990;86:385-391.
2. Hirsh J: Heparin. N Engl J Med 1991;324:1565-574.
3. Stone SR, Hofsteenge J: Kinetics of inhibition of thrombin by hirudin. Biochem 1986;25:4622-4628.
4. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complication after total hip replacement. N Engl J Med 1997;337:1329-1335.
5. Serruys PW, Herrman J-PR, Simon R, et al and the Helvetica Investigators: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
6. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, hirulog, in unstable angina: Anticoagulant, antithrombotic, and clinical effects. Circulation 1993;99;1495-1501.
7. Fox KA: r-Hirudin in unstable angina pectoris: Rationale and preliminary data from the APT pilot study. Eur Heart J 1995;16(suppl D):28-32.
8. Sharma GV, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J: Usefulness and tolerability of hirulog, a direct thrombin inhibitor, in unstable angina pectoris. Am J Cardiol 1993;72:1357-1360.
9. Fuchs J, Cannon CP, and the TIMI 7 Investigators: Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation 1995;92:727-733.
10. Topol EJ, Fuster V, Harrington RA, et al: Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial. Circulation 1994;89:1557-1566.
11. Lidon RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Levesque J: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-1572.
12. Théroux P, Perez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R: Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-2139.
13. Cannon CP, McCabe CH, Henry TD, et al: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
14. Lee LV: Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7-13.
15. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
16. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A randomized trial. Circulation 1997;96:769-777.
17. Organisation to Access Strategies for Ischemic Syndromes (OASIS-2) Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin of death, myocardial infarction, refractory angina, and revacularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet 1999;353:429-438.
18. Neuhaus KL, von Essen R, Tebbe U, et al: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte. Circulation 1994;90:1638-1642.
19. GUSTO IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
20. Antman EM, for the TIMI 9A investigators: Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
21. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. N Engl J Med 1996;335:775-782.
22. Ferguson JJ: Meeting highlights: XIX Congress of the European Society of Cardiology. Circulation 1997;96:3818-3821.
23. Alderman EL: Results from late-breaking clinical trials sessions at ACC '98. J Am Coll Cardiol 1998;32:1-7.
24. Cody RJ: Results from late breaking clinical trials session at ACC '97. J Am Coll Cardiol 1997;30:1-7.
25. White HD, Aylward PE, Collins R, et al: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
26. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lemer RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators: Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. Circulation 2001;103:1838-1843.